Skip to main content

Table 2 Comparison of the clinical characteristics and dasatinib pharmacokinetics in patients with and without a T315I mutation

From: Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation

  T315I (n = 4) Without T315I (n = 7) P-Value
median (quartile 1- quartile 3) median (quartile 1- quartile 3)
Sex Female 2 (50.0) 3 (42.9) 0.6515
Age (year) 67 (64–72) 56 (38.5 - 71) 0.4121
Bodily weight (kg) 50.3 (48.3 - 60.1) 49.0 (44.2 - 52.8) 0.7879
Body surface area (m2) 1.49 (1.46 - 1.57) 1.45 (1.39 - 1.57) 0.6485
White blood cell (*103/mm3) 2.4 (2.4 - 2.5) 3.7 (2.15 - 5.85) 0.3833
Red blood cell (*104 mm3) 248 (241–282) 291 (238–316) 0.8333
Platelet (*104 /mm3) 70 (50.5 - 77.5) 135 (117–167) 0.0167
Aspartate transaminase (IU/L) 32.5 (19.5 - 50) 33 (15.5 - 34) 0.5273
Alanine transaminase (IU/L) 23 (21–79) 23 (14–73.5) 0.7879
Serum albumin (g/dL) 4.3 (4.0 - 4.5) 3.9 (3.3 - 4.2) 0.2303
Total bilirubin (mg/dL) 0.4 (0.4 - 0.5) 0.4 (0.4 - 0.9) 0.9273
Serum creatinine (mg/dL) 0.6 (0.5 - 0.8) 0.6 (0.5 - 0.9) 0.7879
Single dose (mg) 100 (75–100) 100 (100–100) 0.7879
C0h (ng/mL) 0.2 (0.1 - 0.4) 0.0 (0.0 - 0.0) 0.1091
C1h (ng/mL) 13.2 (3.3 - 23.8) 49.0 (23.6 - 66.7) 0.0727
C2h (ng/mL) 22.3 (5.8 - 43.8) 111.6 (65.1 - 122.8) 0.0242
C4h (ng/mL) 34.6 (10.6 - 76.3) 69.7 (66.9 - 95.3) 0.1636
Cmax (ng/mL) 43.8 (19.1 - 77.0) 112.4 (95.3 - 122.8) 0.0242
AUC0-4h (ng·h/mL) 108.3 (49.2 - 139.2) 268.3 (220.0 - 307.3) 0.0061
  1. Data presented as numbers (%) of patients;
  2. Cnh, plasma concentration at n hour after dasatinib administration;
  3. Cmax, maximum plasma concentration less than 4 hours after dasatinib administration;
  4. AUC0-4h, area under the plasma concentration-time curve from 0 to 4 hours.